Welcome to our dedicated page for Option Care Health SEC filings (Ticker: OPCH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Option Care Health, Inc. filings document the public-company disclosures of a Nasdaq-listed provider of home and alternate-site infusion services. Its common stock is registered under the symbol OPCH, and its regulatory record includes Current Reports on Form 8-K, proxy materials, and exhibits tied to operating results and corporate actions.
OPCH filings cover quarterly and annual financial results, non-GAAP measure reconciliations, Regulation FD investor presentations, amendments to its first lien credit agreement, executive officer changes and related severance matters, and definitive proxy disclosures. The proxy record addresses board governance, stockholder voting matters, executive compensation, and capital allocation context for the company's infusion services business.
Option Care Health director Barbara W. Bodem received an equity award of 8,997 common shares on May 20, 2026. The award represents restricted stock units valued at $200,000 based on the issuer’s closing share price on that date and carries no cash exercise cost.
The restricted stock units vest in full on May 20, 2027, meaning Bodem must remain in service through that date to receive the underlying shares. Following this grant, she beneficially owns 21,087 common shares directly, according to the filing.
Wright Norman L. reported acquisition or exercise transactions in this Form 4 filing.
Option Care Health, Inc. director Norman L. Wright reported an equity award rather than a market trade. On May 20, 2026, he received 8,997 restricted stock units, designed to reflect $200,000 of value based on that day’s closing share price. These units vest in full on May 20, 2027, meaning he must remain eligible through that date to receive all shares. Following this award, Wright directly holds 24,498 shares of the company’s common stock.
Option Care Health director Eric Brandt reported equity awards of common stock as part of his compensation. On May 20, 2026 he acquired 2,643 shares of common stock at an indicated value of $22.23 per share through a grant classified as a “grant, award, or other acquisition.”
On the same date, he also received 8,997 restricted stock units in lieu of cash retainer payments, recorded at a price of $0.00 per share. Footnotes state one award was sized to represent $200,000 of value and that both RSU awards vest in full on May 20, 2027. Following these awards, Brandt directly holds 21,999 shares of Option Care Health common stock.
Option Care Health, Inc. reported results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected nine director nominees, each receiving over 143 million votes in favor, with additional broker non-votes recorded on each item.
Stockholders also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 149,076,945 votes for and 1,132,306 against. In a separate non-binding advisory vote, stockholders approved the company’s executive officer compensation, with 141,106,639 votes for and 4,192,721 against.
Option Care Health executive Collin Smyser reported routine equity compensation activity. On May 19, 2026, he exercised 812 Restricted Stock Units, converting them into the same number of common shares. In connection with this, 360 common shares were disposed of to satisfy tax obligations.
After these transactions, Smyser directly owned 75,012 common shares and indirectly held 2,500 common shares through a revocable trust. No open-market purchases or sales were reported, indicating these movements reflect compensation vesting and related tax withholding rather than discretionary trading.
Option Care Health, Inc. furnished an investor presentation in connection with its participation in the Bank of America Health Care Conference. The presentation describes the company as a leading independent provider of home and alternate site infusion services.
Option Care Health reports serving over 315,000 patients in 2025 through more than 5,000 multidisciplinary clinicians, 190+ U.S. locations, about 90 full-service pharmacies, 750+ infusion chairs, and in-network status with the top 10 payers covering 96% of insured lives. For 2026, management highlights priorities that include taking actions to reaccelerate its revenue growth trajectory, reprioritizing capital allocation toward internal investments for profitable growth and share repurchases, and rebuilding momentum through coverage, conversion, and enhanced service levels.
Option Care Health, Inc. director Timothy P. Sullivan reported an open-market purchase of common stock. He bought 24,154 shares of Option Care Health at a weighted average price of $20.6869 per share, through multiple transactions with prices ranging from $20.47 to $20.69. Following these purchases, he directly owns 73,383 shares of the company’s common stock.
Option Care Health Inc. reports FMR LLC beneficial ownership of 6,426,119.18 shares of Common Stock, representing 4.1%. The Schedule 13G/A (Amendment No. 1) shows FMR LLC as filer and names Abigail P. Johnson with dispositive authority; the filing cites Exhibit 99 and a power of attorney effective April 13, 2026.
Option Care Health, Inc. director Harry M. Jansen Kraemer Jr. reported an open-market purchase of 36,610 shares of Common Stock on May 4, 2026. The shares were bought at a weighted average price of $21.4087 per share, with individual trade prices ranging from $21.35 to $21.475. Following this purchase, he directly owns 450,000 shares of Option Care Health, Inc.
Option Care Health, Inc. announced that Christopher L. Grashoff will depart from his role as Chief Growth Officer, effective May 8, 2026. The company states that Mr. Grashoff will receive separation benefits under its Amended and Restated Executive Severance Plan, subject to a general release of claims in favor of the company and his continued compliance with existing restrictive covenants.